Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Apr;7(4):e290-e302.
doi: 10.1016/S2665-9913(24)00307-2. Epub 2025 Jan 21.

Takayasu arteritis: a geographically distant but immunologically proximal MHC-I-opathy

Affiliations
Free article
Review

Takayasu arteritis: a geographically distant but immunologically proximal MHC-I-opathy

Kerem Abacar et al. Lancet Rheumatol. 2025 Apr.
Free article

Abstract

Takayasu arteritis, a granulomatosis vasculitis with a pathogenesis that is poorly defined but known to be associated with HLA-B*52, shares many features with other MHC-I-opathies. In addition to the shared clinical features of inflammatory bowel diseases, cutaneous inflammation, and HLA-B*52, is shared association of an IL12B single- nucleotide polymorphism encoding the common IL-12 and IL-23 p40 subunit, which might affect not only type 17 cytokine responses, but also IFNγ and TNF production-the cardinal type 1 cytokines in granuloma formation. Considering the translational context of responses to TNF inhibition in Takayasu arteritis, in this Personal View we propose Takayasu arteritis as a type 1 MHC-I-opathy. Additionally, type 1 and type 17 T-cell immune responses show immune plasticity, which connects the overlapping features of Takayasu arteritis and spondyloarthritis spectrum disorders, providing a basis for shared anti-TNF responses, and points to p40 and IFNγ cytokine antagonism and potential selective CD8 T-cell repertoire ablation.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests DM has received grant funding and honoraria from AbbVie, Janssen, Eli Lilly, Novartis, and UCB. All other authors declare no competing interests.

Similar articles

Cited by

MeSH terms

LinkOut - more resources